WO2001034183A3 - Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders - Google Patents

Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders Download PDF

Info

Publication number
WO2001034183A3
WO2001034183A3 PCT/EP2000/011251 EP0011251W WO0134183A3 WO 2001034183 A3 WO2001034183 A3 WO 2001034183A3 EP 0011251 W EP0011251 W EP 0011251W WO 0134183 A3 WO0134183 A3 WO 0134183A3
Authority
WO
WIPO (PCT)
Prior art keywords
caspase
eye
diagnose
modulators
blood
Prior art date
Application number
PCT/EP2000/011251
Other languages
French (fr)
Other versions
WO2001034183A2 (en
Inventor
Wim Declercq
Peter Vandenabeele
Saskia Lippens
Original Assignee
Vlaams Interuniv Inst Biotech
Wim Declercq
Peter Vandenabeele
Saskia Lippens
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Interuniv Inst Biotech, Wim Declercq, Peter Vandenabeele, Saskia Lippens filed Critical Vlaams Interuniv Inst Biotech
Priority to EP00977538A priority Critical patent/EP1227834A2/en
Priority to CA002390510A priority patent/CA2390510A1/en
Priority to AU15215/01A priority patent/AU1521501A/en
Publication of WO2001034183A2 publication Critical patent/WO2001034183A2/en
Publication of WO2001034183A3 publication Critical patent/WO2001034183A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6472—Cysteine endopeptidases (3.4.22)
    • C12N9/6475—Interleukin 1-beta convertase-like enzymes (3.4.22.10; 3.4.22.36; 3.4.22.63)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is based on the finding that caspase-14 is expressed in epithelial tissue such as the epidermis, the epithelial layer of the choroid plexus and the pigmented retinal layer. The invention relates to the involvement of caspase-14 in keratinocyte differentiation and in a properly functioning blood-brain barrier and blood-eye barrier. The present invention specifically relates to nucleic acids encoding caspase-14, caspase-14 protein and modulators of caspase-14 expression, activation and bioactivity that can be used to diagnose and/or treat keratinocyte differentiation disorders, disturbances in the blood-eye barrier and brain disorders.
PCT/EP2000/011251 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders WO2001034183A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00977538A EP1227834A2 (en) 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
CA002390510A CA2390510A1 (en) 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
AU15215/01A AU1521501A (en) 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP99203752.3 1999-11-10
EP99203752 1999-11-10
EP00202776 2000-08-04
EP00202776.1 2000-08-04

Publications (2)

Publication Number Publication Date
WO2001034183A2 WO2001034183A2 (en) 2001-05-17
WO2001034183A3 true WO2001034183A3 (en) 2001-11-08

Family

ID=26072576

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/011251 WO2001034183A2 (en) 1999-11-10 2000-11-10 Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders

Country Status (4)

Country Link
EP (1) EP1227834A2 (en)
AU (1) AU1521501A (en)
CA (1) CA2390510A1 (en)
WO (1) WO2001034183A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1384468A1 (en) * 2002-07-25 2004-01-28 Cognis France S.A. Method for protecting and for modulating tight junctions
EP1384469A1 (en) * 2002-07-25 2004-01-28 Cognis France S.A. Method for protecting and for modulating tight junctions
WO2008025830A2 (en) * 2006-09-01 2008-03-06 Vib Vzw Pharmaceutical and sunscreen compositions comprising caspase-14
JP5562015B2 (en) * 2009-12-04 2014-07-30 株式会社 資生堂 Screening method for skin barrier function recovery promoting substance

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0305097A2 (en) * 1987-08-25 1989-03-01 Scotia Holdings Plc Nutritional supplement
EP0353772A2 (en) * 1988-08-05 1990-02-07 Oncogen Limited Partnership Psoriasis treatment with TGF-beta2
US5037816A (en) * 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
WO1992013551A1 (en) * 1991-02-04 1992-08-20 Oncogene Science, Inc. Inhibition of multidrug transport by transforming growth factor beta and uses thereof
FR2726187A1 (en) * 1994-10-26 1996-05-03 Jean Noel Thorel Topical compsns. contg. calcium chloride
EP0803248A2 (en) * 1996-04-25 1997-10-29 Unilever Plc Skin care compositions containing retinol or retinyl ester
WO1999010504A2 (en) * 1997-08-26 1999-03-04 Idun Pharmaceuticals, Inc. Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
WO1999023106A1 (en) * 1997-10-30 1999-05-14 Human Genome Sciences, Inc. Caspase-14 polypeptides
WO2000004169A1 (en) * 1998-07-17 2000-01-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New caspase homologue

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037816A (en) * 1984-11-02 1991-08-06 The General Hospital Corporation Method of treating psoriasis
EP0305097A2 (en) * 1987-08-25 1989-03-01 Scotia Holdings Plc Nutritional supplement
EP0353772A2 (en) * 1988-08-05 1990-02-07 Oncogen Limited Partnership Psoriasis treatment with TGF-beta2
WO1992013551A1 (en) * 1991-02-04 1992-08-20 Oncogene Science, Inc. Inhibition of multidrug transport by transforming growth factor beta and uses thereof
FR2726187A1 (en) * 1994-10-26 1996-05-03 Jean Noel Thorel Topical compsns. contg. calcium chloride
EP0803248A2 (en) * 1996-04-25 1997-10-29 Unilever Plc Skin care compositions containing retinol or retinyl ester
WO1999010504A2 (en) * 1997-08-26 1999-03-04 Idun Pharmaceuticals, Inc. Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use
WO1999023106A1 (en) * 1997-10-30 1999-05-14 Human Genome Sciences, Inc. Caspase-14 polypeptides
WO2000004169A1 (en) * 1998-07-17 2000-01-27 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw New caspase homologue

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AWASTHI P K ET AL: "Effect of oral lithium on the action of various C.N.S. active drugs.", INDIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 40, no. 3, 1996, pages 241 - 244, XP001009815, ISSN: 0019-5499 *
CRAEN VAN DE M ET AL: "IDENTIFICATION OF A NEW CASPASE HOMOLOGUE: CASPASE-14", CELL DEATH AND DIFFERENTIATION,GB,EDWARD ARNOLD, OXFORD, vol. 5, no. 10, 1998, pages 838 - 847, XP000877350, ISSN: 1350-9047 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1990, KUNIYUKI S: "EFFECTS OF RETINOID 1-ALPHA 25 DIHYDROXYVITAMIN D-3 AND CORTICOSTEROID ON THE CULTURED HUMAN EPIDERMAL KERATINOCYTES LIGHT AND ELECTRON MICROSCOPIC STUDY", XP002170338, Database accession no. PREV199192088291 *
HOHEISEL DIRK ET AL: "Hydrocortisone reinforces the blood-brain barrier properties in a serum free cell culture system.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 244, no. 1, 6 March 1998 (1998-03-06), pages 312 - 316, XP002170337, ISSN: 0006-291X *
JOURNAL OF THE OSAKA CITY MEDICAL CENTER, vol. 39, no. 3, 1990, pages 553 - 574, ISSN: 0386-4103 *
KAYA M ET AL: "Chemical induction of fenestrae in vessels of the blood-brain barrier.", EXPERIMENTAL NEUROLOGY, vol. 142, no. 1, 1996, pages 6 - 13, XP001009858, ISSN: 0014-4886 *

Also Published As

Publication number Publication date
AU1521501A (en) 2001-06-06
EP1227834A2 (en) 2002-08-07
CA2390510A1 (en) 2001-05-17
WO2001034183A2 (en) 2001-05-17

Similar Documents

Publication Publication Date Title
WO2005004985A3 (en) Device for treatment of degenerative retinal disease via electrical stimulation of surface stuctures of the eyeball
EP0845268A3 (en) Composition for treating cornea
CA2440260A1 (en) Methods and apparatus for effectuating a lasting change in a neural-function of a patient
WO2004069870A3 (en) Differentially expressed nucleic acids in the blood-brain barrier under inflammatory conditions
WO2003039622A3 (en) Novel iontophoretic drug delivery systems
PT927560E (en) DEVICE FOR THE INTRA-OCULAR TRANSFER OF IONTOFORESE ACTIVE PRODUCTS
WO2001066595A3 (en) Human fgf-23 gene and gene expression products
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2003026565A3 (en) Composition and treatment method for brain and spinal cord injuries
WO2001066596A3 (en) Human fgf-23 gene and gene expression products
WO2000033814A3 (en) Method for administering agents to the central nervous system
WO2001034183A3 (en) Use of caspase-14 and caspase-14 modulators to diagnose and/or treat skin, eye and brain disorders
US20220023654A1 (en) Enhancing epithelial integrity by a sequence of magnetic pulses
WO2002065943A3 (en) Ocular tear growth factor-like protein
Halata et al. Anatomy of receptors
DE69028877D1 (en) Use of phenylethanolamines for the manufacture of medicines for eye diseases
MXPA03001160A (en) Method of treating neurodegenerative disorders of the retina and optic nerve head.
WO1997002002A3 (en) Use of polyolpoly-12-hydroxystearates
Gruart et al. Signalling properties of identified deep cerebellar nuclear neurons related to eye and head movements in the alert cat.
WO2003030836A3 (en) Neuronal regeneration
EP1297849A4 (en) Remedial agent for optic nerve disease and the like
WO2004056386A3 (en) Nucleic acids involved in blood-brain barrier control
DK0839137T3 (en) Aromatic carboxylic acid diamides with antigastrin action, process for their preparation and their use as drugs
EP0784983A3 (en) Use of extracellular hemoglobin
WO2011058449A3 (en) Ophthalmic preparations based on bdnf (brain-derived neurotrophic factor) and their use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2390510

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10141722

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000977538

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000977538

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000977538

Country of ref document: EP

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)